ACP
BMY icon

Argyle Capital Partners’s Bristol-Myers Squibb BMY Stock Holding History

Argyle Capital Partners’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$393K Sell
6,482
-3,317
-34% -$193K 0.28% 99
2025
Q4 		$529K Sell
9,799
-473
-5% -$22.8K 0.39% 80
2025
Q3 		$463K Buy
10,272
+687
+7% +$32.1K 0.33% 89
2025
Q2 		$444K Sell
9,585
-3,764
-28% -$185K 0.37% 80
2025
Q1 		$814K Sell
13,349
-836
-6% -$48.7K 0.7% 50
2024
Q4 		$802K Buy
+14,185
New +$793K 0.69% 49

Other funds holding BMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Argyle Capital Partners's BMY Position: Q1 2026 in Review

Argyle Capital Partners reduced its Bristol-Myers Squibb (BMY) stake by 34% in Q1 2026, selling an estimated $193K and leaving 6,482 shares worth $393K. The position accounts for 0.28% of the portfolio, ranked #99.

Argyle Capital Partners first reported a position in BMY in Q4 2024 and has held it in 6 quarters since. The position peaked at $814K in Q1 2025. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Argyle Capital Partners held 6,482 shares of Bristol-Myers Squibb worth $393K as of Q1 2026.
  • Argyle Capital Partners sold 3,317 Bristol-Myers Squibb shares in Q1 2026, an estimated $193K.
  • Bristol-Myers Squibb made up 0.28% of Argyle Capital Partners's portfolio in Q1 2026, its #99 holding.
  • Argyle Capital Partners first reported a position in Bristol-Myers Squibb in Q4 2024 and has held it in 6 quarters since.
  • Argyle Capital Partners's Bristol-Myers Squibb position peaked at $814K in Q1 2025.
  • 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Argyle Capital Partners's 13F filing for Q1 2026, filed 7 May 2026.